PEP/NEWS — Peptide intel. Daily.

DA-1726 GLP-1/GCGR DUAL AGONIST PRODUCED 9.1% WEIGHT LOSS BY DAY 54 IN PHASE 1 HIGH-DOSE COHORTLIFE BIO FIRST PATIENT DOSED IN OSK EPIGENETIC REPROGRAMMING PHASE 1 EYE TRIALPAI-1 LOSS-OF-FUNCTION MUTATION IN HUMANS LINKED TO UP TO 7 EXTRA YEARS OF LIFELOW-DOSE CONTINUOUS RAPAMYCIN OUTPERFORMS HIGH-DOSE INTERMITTENT IN AGING IMMUNE REMODELING DATAEVIPEDIA.AI NOW COVERS 500+ LONGEVITY INTERVENTIONS WITH FULL EVIDENCE GRADINGMAGNESIUM IDENTIFIED AS MITOCHONDRIAL BIOENERGETIC CHECKPOINT LINKING AGING TO METABOLIC DISEASEBPC-157 + TB-500 WOLVERINE BLEND: OVERLAPPING ANGIOGENESIS AND ACTIN REMODELING PATHWAYS DOCUMENTED IN LITERATUREDRIED BLOOD SPOT HOME PROTEOMICS KIT FROM ALAMAR BIOSCIENCES CUTS CLINIC REQUIREMENT FOR LONGEVITY STUDIES DA-1726 GLP-1/GCGR DUAL AGONIST PRODUCED 9.1% WEIGHT LOSS BY DAY 54 IN PHASE 1 HIGH-DOSE COHORTLIFE BIO FIRST PATIENT DOSED IN OSK EPIGENETIC REPROGRAMMING PHASE 1 EYE TRIALPAI-1 LOSS-OF-FUNCTION MUTATION IN HUMANS LINKED TO UP TO 7 EXTRA YEARS OF LIFELOW-DOSE CONTINUOUS RAPAMYCIN OUTPERFORMS HIGH-DOSE INTERMITTENT IN AGING IMMUNE REMODELING DATAEVIPEDIA.AI NOW COVERS 500+ LONGEVITY INTERVENTIONS WITH FULL EVIDENCE GRADINGMAGNESIUM IDENTIFIED AS MITOCHONDRIAL BIOENERGETIC CHECKPOINT LINKING AGING TO METABOLIC DISEASEBPC-157 + TB-500 WOLVERINE BLEND: OVERLAPPING ANGIOGENESIS AND ACTIN REMODELING PATHWAYS DOCUMENTED IN LITERATUREDRIED BLOOD SPOT HOME PROTEOMICS KIT FROM ALAMAR BIOSCIENCES CUTS CLINIC REQUIREMENT FOR LONGEVITY STUDIES

Last updated June 10, 2026 — I read this morning's peptide research and picked the items that mattered. Fresh brief tomorrow.

Featured Briefs

◤ From the network · Research Vials

PEPTIDE RESEARCH TRENDS TO WATCH IN 2026

The five biggest trends shaping peptide research in 2026 — from GLP-1 agonist evolution to mitochondrial peptides, AI-driven discovery, and the post-Peptide Sciences landscape.

Research Vials
◤ Article · Peptide-anchored

METAVIA'S GLP-1/GCGR DUAL AGONIST HITS 9.1% WEIGHT LOSS IN 54 DAYS...

MetaVia's DA-1726 — a once-weekly GLP-1R/GCGR (glucagon-like peptide-1 and glucagon receptor) dual agonist — produced average body weight reductions of 9.1% by day 54 in its highest-dose Phase 1 cohort. Waist circumference dropped nearly 6 cm in the same window. The data, presented at the American Diabetes Association 2026 Scientific Sessions, put DA-1726 in direct competition with the semaglutide and tirzepatide class — but with a dual-receptor mechanism that may hit fat tissue harder.

Longevity Technology
▶ Video

SLU-PP-332 BODYBUILDING?

Struggling to improve endurance, recovery, and fat loss without sacrificing muscle mass? In this video, I break down how SLU-PP-332 may support mitochondrial health, increase oxidative capacity, and help bodybuilders and athletes build a st

Regan Archibald

More Headlines